Your entry is only as good as your exit strategy...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Heating up..volume commin...cmon .72 break
NTWK...0.6302 X .638...looking for a break of .72
ENER..$1.14 X $1.15
DEXO...$1.74 X $1.75
ENER ....$1.10 X $1.11
XIDE...$3.50 X $3.51
ZOOM... $1.50 X $1.51 here we go...
ZOOM...here we go....
MWWC.... .01 X .011
ZOOM..$1.43...this holds it's going...we shall see
Good Morning...Enjoy and have a great day....
STP...$3.52...Huge News..
DuPont and Suntech Power Holdings Co., Ltd. (NYSE: STP), the world's largest producer of solar panels, have signed a strategic agreement to help increase the supply of photovoltaic materials and technologies for the growing global market for solar energy. The agreement focuses on technology advancements, supply chain optimization cost reduction initiatives, and DuPont(TM) Tedlar® polyvinyl fluoride film supply. The companies also are pursuing co-marketing opportunities. The companies' goal is to achieve faster and broader adoption of solar energy to reduce the world's dependence on fossil fuels. They intend to achieve the goal by further improving the technology for solar energy and helping reduce its costs and building greater awareness of its benefits to consumers.
"We're partnering with leading photovoltaic component suppliers around the world as we continue to make solar affordable for everyone, everywhere. With innovative companies like DuPont, the United States is a major contributor to the global photovoltaic supply chain and a net exporter of solar products to China and global markets," said Eric Luo, senior vice president of global supply chain, Suntech. "Creating higher efficiency solar cells and further extending the long life of solar modules is critical to achieving affordable solar power, and we've worked closely and very successfully with DuPont in this regard. We're taking our collaboration to the next level with this agreement."
In November 2011, Suntech recognized DuPont with its annual Supplier Excellence Award for providing superior supply and technical service, product innovation and collaboration. DuPont supplies DuPont(TM) Solamet® photovoltaic metallization pastes to help enhance the efficiency of solar cells made by Suntech, as well as DuPont(TM) Tedlar® polyvinyl fluoride film used in protective backsheets for Suntech solar modules. These materials are part of DuPont's broad and growing portfolio of products that improve the efficiency and lifetime of solar cells and modules, and help reduce overall system costs to make solar more competitive with traditional sources of energy.
"DuPont and Suntech have the highest standards for product quality, and sustainability is an important value for each of us. With these shared values, we look forward to bringing our offerings to more consumers as the global industry continues to grow," said David B. Miller, president, DuPont Electronics & Technologies. "Global partnerships, such as our work with Suntech, have been central to the solar industry's growth. Our work together in Masdar is a prime example of the benefits of our collaboration, and of solar energy."
The DuPont collaboration with Suntech was featured as part of a short documentary titled, "City of Science, City of Hope," that recently aired during the BBC News "Horizons" program series. The documentary highlights the role of DuPont materials that enable Suntech solar modules to help power the city of Masdar - one of the most sustainable communities on the planet, and a model of what green urban development can be.
Suntech Power Holdings Co., Ltd. (NYSE: STP) produces industry-leading solar products for residential, commercial, industrial, and utility applications. With regional headquarters in China, Switzerland, and the United States, and gigawatt-scale manufacturing worldwide, Suntech has delivered more than 20 million photovoltaic panels to over 1,000 customers in more than 80 countries. Suntech's pioneering R&D creates customer-centric innovations that are driving solar to grid parity against fossil fuels. Suntech's mission is to provide everyone with reliable access to nature's cleanest and most abundant energy source. For more information about Suntech's people and products, please visit http://www.suntech-power.com.
DuPont(TM) Solamet® photovoltaic metallizations and Tedlar® polyvinyl fluoride films are part of a broad and growing portfolio of products represented by DuPont Photovoltaic Solutions, which connects science and technology from across the company on a global scale to help support the dramatic growth in the photovoltaic industry. To learn more about DuPont Photovoltaic Solutions, visit http://photovoltaics.dupont.com.
DuPont (NYSE: DD) has been bringing world-class science and engineering to the global marketplace in the form of innovative products, materials, and services since 1802. The company believes that by collaborating with customers, governments, NGOs, and thought leaders we can help find solutions to such global challenges as providing enough healthy food for people everywhere, decreasing dependence on fossil fuels, and protecting life and the environment. For additional information about DuPont and its commitment to inclusive innovation, please visit http://www.dupont.com.
Forward-Looking Statements: This news release contains forward-looking statements based on management's current expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects," "anticipates," "plans," "intends," "projects," "indicates," and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents filed with the Securities and Exchange Commission by DuPont, particularly its latest annual report on Form 10-K and quarterly report on Form 10-Q, as well as others, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw materials, research and development of new products, including regulatory approval and market acceptance; seasonality of sales of agricultural products; and severe weather events that cause business interruptions, including plant and power outages, or disruptions in supplier and customer operations. The company undertakes no duty to update any forward-looking statements as a result of future developments or new information.
The DuPont Oval Logo, DuPont(TM), The miracles of science(TM), Solamet® and Tedlar® are registered trademarks or trademarks of DuPont or its affiliates.
A high resolution image can be downloaded at: http://www2.dupont.com/Photovoltaics/en_US/assets/images/gallery/suntech-china_hirez.jpg
Caption: Suntech and DuPont have signed a strategic sourcing agreement to drive faster and broader adoption of solar energy, reducing the world's dependence on fossil fuels.
SOURCE DuPont
STP...$ 3.25...Huge News...
DuPont and Suntech Power Holdings Co., Ltd. (NYSE: STP), the world's largest producer of solar panels, have signed a strategic agreement to help increase the supply of photovoltaic materials and technologies for the growing global market for solar energy. The agreement focuses on technology advancements, supply chain optimization cost reduction initiatives, and DuPont(TM) Tedlar® polyvinyl fluoride film supply. The companies also are pursuing co-marketing opportunities. The companies' goal is to achieve faster and broader adoption of solar energy to reduce the world's dependence on fossil fuels. They intend to achieve the goal by further improving the technology for solar energy and helping reduce its costs and building greater awareness of its benefits to consumers.
"We're partnering with leading photovoltaic component suppliers around the world as we continue to make solar affordable for everyone, everywhere. With innovative companies like DuPont, the United States is a major contributor to the global photovoltaic supply chain and a net exporter of solar products to China and global markets," said Eric Luo, senior vice president of global supply chain, Suntech. "Creating higher efficiency solar cells and further extending the long life of solar modules is critical to achieving affordable solar power, and we've worked closely and very successfully with DuPont in this regard. We're taking our collaboration to the next level with this agreement."
In November 2011, Suntech recognized DuPont with its annual Supplier Excellence Award for providing superior supply and technical service, product innovation and collaboration. DuPont supplies DuPont(TM) Solamet® photovoltaic metallization pastes to help enhance the efficiency of solar cells made by Suntech, as well as DuPont(TM) Tedlar® polyvinyl fluoride film used in protective backsheets for Suntech solar modules. These materials are part of DuPont's broad and growing portfolio of products that improve the efficiency and lifetime of solar cells and modules, and help reduce overall system costs to make solar more competitive with traditional sources of energy.
"DuPont and Suntech have the highest standards for product quality, and sustainability is an important value for each of us. With these shared values, we look forward to bringing our offerings to more consumers as the global industry continues to grow," said David B. Miller, president, DuPont Electronics & Technologies. "Global partnerships, such as our work with Suntech, have been central to the solar industry's growth. Our work together in Masdar is a prime example of the benefits of our collaboration, and of solar energy."
The DuPont collaboration with Suntech was featured as part of a short documentary titled, "City of Science, City of Hope," that recently aired during the BBC News "Horizons" program series. The documentary highlights the role of DuPont materials that enable Suntech solar modules to help power the city of Masdar - one of the most sustainable communities on the planet, and a model of what green urban development can be.
Suntech Power Holdings Co., Ltd. (NYSE: STP) produces industry-leading solar products for residential, commercial, industrial, and utility applications. With regional headquarters in China, Switzerland, and the United States, and gigawatt-scale manufacturing worldwide, Suntech has delivered more than 20 million photovoltaic panels to over 1,000 customers in more than 80 countries. Suntech's pioneering R&D creates customer-centric innovations that are driving solar to grid parity against fossil fuels. Suntech's mission is to provide everyone with reliable access to nature's cleanest and most abundant energy source. For more information about Suntech's people and products, please visit http://www.suntech-power.com.
DuPont(TM) Solamet® photovoltaic metallizations and Tedlar® polyvinyl fluoride films are part of a broad and growing portfolio of products represented by DuPont Photovoltaic Solutions, which connects science and technology from across the company on a global scale to help support the dramatic growth in the photovoltaic industry. To learn more about DuPont Photovoltaic Solutions, visit http://photovoltaics.dupont.com.
DuPont (NYSE: DD) has been bringing world-class science and engineering to the global marketplace in the form of innovative products, materials, and services since 1802. The company believes that by collaborating with customers, governments, NGOs, and thought leaders we can help find solutions to such global challenges as providing enough healthy food for people everywhere, decreasing dependence on fossil fuels, and protecting life and the environment. For additional information about DuPont and its commitment to inclusive innovation, please visit http://www.dupont.com.
Forward-Looking Statements: This news release contains forward-looking statements based on management's current expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects," "anticipates," "plans," "intends," "projects," "indicates," and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents filed with the Securities and Exchange Commission by DuPont, particularly its latest annual report on Form 10-K and quarterly report on Form 10-Q, as well as others, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw materials, research and development of new products, including regulatory approval and market acceptance; seasonality of sales of agricultural products; and severe weather events that cause business interruptions, including plant and power outages, or disruptions in supplier and customer operations. The company undertakes no duty to update any forward-looking statements as a result of future developments or new information.
The DuPont Oval Logo, DuPont(TM), The miracles of science(TM), Solamet® and Tedlar® are registered trademarks or trademarks of DuPont or its affiliates.
A high resolution image can be downloaded at: http://www2.dupont.com/Photovoltaics/en_US/assets/images/gallery/suntech-china_hirez.jpg
Caption: Suntech and DuPont have signed a strategic sourcing agreement to drive faster and broader adoption of solar energy, reducing the world's dependence on fossil fuels.
SOURCE DuPont
APRE...News..
Aperture Health, Inc. Enters Into Discussions to Form a Joint Venture to Offer Its' Services to the Pet Med Marketplace
7:00 AM ET 2/1/12 | PR Newswire
Aperture Health, Inc. (OTC: APRE) announced that it has entered into planning discussions with small and large animal veterinarians and other industry professionals, with a specific focus on the equine show and racing disciplines. The Pet Med industry in the United States is in excess of $4B. Aperture's CEO, James Hennig, R.Ph. became certified in veterinary compounding to be able to move the company into the fast growing pet med arena. Triad has historically been a provider of infusion therapies to major vet hospitals in the metro NJ area.
James Hennig, R.Ph, Chief Executive Officer and Chairman of the Board of Directors commented, "We are very excited at the prospects of forming partnerships and alliances with noted large and small animal Veterinarians and in particular other equine sport professionals who require our capabilities to provide complex compounding and IV services. The rapid growth in this industry and the high margins attributable to penetrating this relatively untapped market will provide Aperture and Triad tremendous opportunity to increase and accelerate revenue and bottom line growth."
About Aperture Health, and Triad TherapeuticsAperture Health through its wholly owned subsidiary Triad Therapeutics operates a fully JCAHO accredited home IV therapy company, achieving this "gold standard" status in 2007. The company has built a well respected reputation in its industry for its therapy expertise and commitment to care for its patient clients. The company services clients throughout the States of New Jersey, New York and Connecticut, providing opportunity for organic growth. Triad's full time marketing and sales personnel continuously represent the company in the core services areas, growing and maintaining the company's referral source base. Patient referrals are made from physicians, hospitals, insurance companies, veterinarians and hospice care providers that have established a professional rapport with Triad.
Safe HarborCertain statements in this news release are forward-looking, including (without limitation) growing revenues and earnings, expected results from current projects and attracting new business. Undue reliance should not be placed on such forward-looking statements because the matters they describe are subject to known and unknown risks, uncertainties and other unpredictable factors, many of which are beyond the Company's control. The Company's actual results, performance and trends could differ materially from those indicated or implied by such statements as a result of various factors, including (without limitation) the continued strengthening of Triad's selling and marketing functions, continued customer satisfaction, contract renewal, new product development, continued availability of capable dedicated personnel, continued cost management, success and availability of acquisitions, availability of financing and other factors, as well as by factors applicable to most companies such as general economic, competitive and other business and civil conditions. Information regarding certain of those and other risk factors and cautionary statements that could affect future results, performance or trends is discussed in the Company's OTC Disclosure Statement and unaudited management financials posted on www.pinksheets.com . All of the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date hereof.
SOURCE Aperture Health, Inc.
GNBT...News..Generex Announces Patent Award for its Core Vaccine Technologies in Japan
8:00 AM ET 2/1/12 | PR Newswire
Generex Biotechnology Corporation (OTCBB: GNBT.OB) announced today that its wholly owned subsidiary, Antigen Express, Inc., has been awarded a Japanese Patent centering on its Ii-Key technology for the development of immunotherapeutic vaccines. A number of products developed with this technology are currently in clinical development. The patent helps to secure the novel Antigen Express vaccine technology platform in the international community. International counterparts have been granted in Australia, China, and the United States. The European counterpart has been allowed, and the Canadian application is pending.
(Photo: http://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b )
About AE37 and Ii-Key Hybrid Platform Technology
Antigen Express is a platform technology and product-based company developing proprietary vaccine formulations for large, unmet medical needs. The Company's Ii-Key Hybrid technology platform entails the modification of fragments of antigens to increase their potency in stimulating critical members of the immune response, known as CD4+ T helper cells. Incorporating the Ii-Key modification along with tumor-associated antigens can greatly enhance the immune system's ability to recognize and destroy cancer cells bearing any of the targeted antigens as well as increasing immunological memory.
The first product candidate utilizing the Company's novel Ii-Key Hybrid technology platform is a HER-2/neu Peptide Vaccine (AE37). This "off-the-shelf" cancer immunotherapy product candidate is easier and less costly to produce than comparable cell-based approaches. AE37 is derived from a peptide fragment of the human epidermal growth factor receptor 2 (HER2) oncoprotein, which is expressed in a variety of tumors including 75-80% of breast cancers as well as a high percentage of prostate, ovarian, and other cancers. AE37 represents the only HER2-based peptide vaccine currently being studied in a randomized trial and its use is not restricted to patients with a particular type of human leukocyte antigen (HLA) peptide.
About Breast Cancer
According to the American Cancer Society, more than 232,000 women will be diagnosed with breast cancer, and nearly 40,000 will die from the disease, in 2011. For women whose cancer tests positive for increased quantities of the HER2, approved targeted therapies include trastuzumab (Herceptin®; Roche-Genentech). However, only 25% of breast cancer patients have HER2 levels high enough to be eligible for Herceptin. AE37 is positioned initially as an adjuvant therapy for at least 50% of breast cancer patients; i.e., those with low-to-intermediate levels of HER2 expression.
About Generex Biotechnology Corporation
Generex, the parent company of Antigen Express, is also engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T-helper stimulation in immunotherapy. One of its platform technologies relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.
Cautionary Note Regarding Forward-Looking Statements
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials or ultimate regulatory approval cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials or when it will obtain ultimate regulatory approval by a particular regulatory agency. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
SOURCE Generex Biotechnology Corporation
GNBT..News...Generex Announces Patent Award for its Core Vaccine Technologies in Japan
8:00 AM ET 2/1/12 | PR Newswire
Generex Biotechnology Corporation (OTCBB: GNBT.OB) announced today that its wholly owned subsidiary, Antigen Express, Inc., has been awarded a Japanese Patent centering on its Ii-Key technology for the development of immunotherapeutic vaccines. A number of products developed with this technology are currently in clinical development. The patent helps to secure the novel Antigen Express vaccine technology platform in the international community. International counterparts have been granted in Australia, China, and the United States. The European counterpart has been allowed, and the Canadian application is pending.
(Photo: http://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b )
About AE37 and Ii-Key Hybrid Platform Technology
Antigen Express is a platform technology and product-based company developing proprietary vaccine formulations for large, unmet medical needs. The Company's Ii-Key Hybrid technology platform entails the modification of fragments of antigens to increase their potency in stimulating critical members of the immune response, known as CD4+ T helper cells. Incorporating the Ii-Key modification along with tumor-associated antigens can greatly enhance the immune system's ability to recognize and destroy cancer cells bearing any of the targeted antigens as well as increasing immunological memory.
The first product candidate utilizing the Company's novel Ii-Key Hybrid technology platform is a HER-2/neu Peptide Vaccine (AE37). This "off-the-shelf" cancer immunotherapy product candidate is easier and less costly to produce than comparable cell-based approaches. AE37 is derived from a peptide fragment of the human epidermal growth factor receptor 2 (HER2) oncoprotein, which is expressed in a variety of tumors including 75-80% of breast cancers as well as a high percentage of prostate, ovarian, and other cancers. AE37 represents the only HER2-based peptide vaccine currently being studied in a randomized trial and its use is not restricted to patients with a particular type of human leukocyte antigen (HLA) peptide.
About Breast Cancer
According to the American Cancer Society, more than 232,000 women will be diagnosed with breast cancer, and nearly 40,000 will die from the disease, in 2011. For women whose cancer tests positive for increased quantities of the HER2, approved targeted therapies include trastuzumab (Herceptin®; Roche-Genentech). However, only 25% of breast cancer patients have HER2 levels high enough to be eligible for Herceptin. AE37 is positioned initially as an adjuvant therapy for at least 50% of breast cancer patients; i.e., those with low-to-intermediate levels of HER2 expression.
About Generex Biotechnology Corporation
Generex, the parent company of Antigen Express, is also engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T-helper stimulation in immunotherapy. One of its platform technologies relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.
Cautionary Note Regarding Forward-Looking Statements
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials or ultimate regulatory approval cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials or when it will obtain ultimate regulatory approval by a particular regulatory agency. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
SOURCE Generex Biotechnology Corporation
GNBT...News..Generex Announces Patent Award for its Core Vaccine Technologies in Japan
8:00 AM ET 2/1/12 | PR Newswire
Generex Biotechnology Corporation (OTCBB: GNBT.OB) announced today that its wholly owned subsidiary, Antigen Express, Inc., has been awarded a Japanese Patent centering on its Ii-Key technology for the development of immunotherapeutic vaccines. A number of products developed with this technology are currently in clinical development. The patent helps to secure the novel Antigen Express vaccine technology platform in the international community. International counterparts have been granted in Australia, China, and the United States. The European counterpart has been allowed, and the Canadian application is pending.
(Photo: http://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b )
About AE37 and Ii-Key Hybrid Platform Technology
Antigen Express is a platform technology and product-based company developing proprietary vaccine formulations for large, unmet medical needs. The Company's Ii-Key Hybrid technology platform entails the modification of fragments of antigens to increase their potency in stimulating critical members of the immune response, known as CD4+ T helper cells. Incorporating the Ii-Key modification along with tumor-associated antigens can greatly enhance the immune system's ability to recognize and destroy cancer cells bearing any of the targeted antigens as well as increasing immunological memory.
The first product candidate utilizing the Company's novel Ii-Key Hybrid technology platform is a HER-2/neu Peptide Vaccine (AE37). This "off-the-shelf" cancer immunotherapy product candidate is easier and less costly to produce than comparable cell-based approaches. AE37 is derived from a peptide fragment of the human epidermal growth factor receptor 2 (HER2) oncoprotein, which is expressed in a variety of tumors including 75-80% of breast cancers as well as a high percentage of prostate, ovarian, and other cancers. AE37 represents the only HER2-based peptide vaccine currently being studied in a randomized trial and its use is not restricted to patients with a particular type of human leukocyte antigen (HLA) peptide.
About Breast Cancer
According to the American Cancer Society, more than 232,000 women will be diagnosed with breast cancer, and nearly 40,000 will die from the disease, in 2011. For women whose cancer tests positive for increased quantities of the HER2, approved targeted therapies include trastuzumab (Herceptin®; Roche-Genentech). However, only 25% of breast cancer patients have HER2 levels high enough to be eligible for Herceptin. AE37 is positioned initially as an adjuvant therapy for at least 50% of breast cancer patients; i.e., those with low-to-intermediate levels of HER2 expression.
About Generex Biotechnology Corporation
Generex, the parent company of Antigen Express, is also engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T-helper stimulation in immunotherapy. One of its platform technologies relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.
Cautionary Note Regarding Forward-Looking Statements
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials or ultimate regulatory approval cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials or when it will obtain ultimate regulatory approval by a particular regulatory agency. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
SOURCE Generex Biotechnology Corporation
ATHX...$1.87..News..look for a bounce off the 50ma on this news..
Athersys Awarded $3.6 Million in Grant Funding for Stem Cell Product Development
7:00 AM ET 2/1/12 | GlobeNewswire
Athersys, Inc. (Nasdaq:ATHX), a leader in the emerging field of regenerative medicine, announced today grant funding aggregating $3.6 million to further advance its MultiStem(R) product programs and cell therapy platform. Specifically, Athersys was awarded a SBIR Fast-Track grant of up to $1.9 million from the National Institute of Neurological Disorders and Stroke (NINDS) to develop MultiStem for the treatment of traumatic brain injury (TBI). In addition, Athersys' subsidiary based in Belgium, ReGenesys BVBA, was awarded a $1.2 million (EURO0.9 million) grant from the Belgium's Agency for Innovation by Science and Technology (IWT) to further develop cell therapy formulations and manufacturing capabilities. The company has also been awarded funding recently to work in other areas, such as using MultiStem to treat chronic cardiovascular disease.
"These grant awards provide us with additional funding to support further development of MultiStem in specific therapeutic areas, as well as enhance our manufacturing platform," said Dr. Gil Van Bokkelen, Athersys Chairman & CEO. "Historically, we have been very successful at obtaining this type of funding, which reflects our commitment to outstanding science and technology development, and development of innovative new therapies."
NINDS TBI Grant
The work under the NINDS grant to develop MultiStem for the treatment of TBI will be conducted in collaboration with researchers at The University of Texas Health Science Center at Houston (UTHealth) Medical School. The research program will include preclinical safety and efficacy studies required to support an Investigational New Drug (IND) application and the clinical investigation of MultiStem treatment of TBI.
TBI is a serious clinical problem that affects young people, members of the armed services and other adults. According to the Centers for Disease Control, there are nearly 1.4 million emergency room visits each year as a result of TBI, resulting in 275,000 hospitalizations and 52,000 deaths annually.
"Based on the results from studies conducted with our collaborators, we believe MultiStem could have a significant impact in treating damage from acute neurological injury, such as TBI, ischemic stroke and other indications," said Dr. Van Bokkelen.
Dr. Charles Cox, Jr., who directs the multi-disciplinary effort at UTHealth Medical School that is focused on stem cell therapy for traumatic brain injury and related neurological injuries, will lead the collaboration with Athersys. "Our prior work with Athersys has demonstrated that MultiStem modulates the inflammatory component of secondary brain injury in preclinical models of TBI," said Dr. Cox, professor of pediatric surgery at UTHealth and director of the pediatric trauma program at Children's Memorial Hermann Hospital in Houston. "This is an area of tremendous unmet medical need, which carries both a high cost burden, as well as impacting patient and family quality of life. We will build on this promising work to advance the application of this cell therapy into clinical studies."
IWT Grant
The IWT grant will fund a product and process development program undertaken in Belgium by ReGenesys, Athersys' affiliate. A principal focus of these efforts will be the continued development of serum-free formulations for the manufacture of MultiStem and related cell therapy products. ReGenesys researchers will collaborate with researchers from the Katholieke Universiteit of Leuven, as well as certain corporate partners to complete the program.
"Our ReGenesys affiliate plays a significant role in the development of improved process and manufacturing approaches for cell therapy products," said William Lehmann, President and COO of Athersys, and Manager of ReGenesys. "We expect this grant-funded work to have substantial impact on product manufacturing and clinical development in Europe and globally."
About MultiStem
MultiStem(R) cell therapy is a patented product that has shown the ability to promote tissue repair and healing in a variety of ways, such as through the production of multiple therapeutic factors produced in response to signals of inflammation and tissue damage. MultiStem has demonstrated therapeutic potential for the treatment of inflammatory and immune disorders, neurological conditions, and cardiovascular disease, as well as other areas, and represents a unique "off-the-shelf" stem cell product that can be manufactured in a scalable manner, may be stored for years in frozen form, and is administered without tissue matching or the need for immune suppression. The product is extensively characterized for safety, consistency and potency. Athersys has forged strategic partnerships with Pfizer Inc. to develop MultiStem for inflammatory bowel disease and with RTI Biologics, Inc. to develop cell therapy for use with a bone allograft product in the orthopedic market.
About Athersys
Athersys is a clinical stage biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem(R) cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product platform for disease indications in the cardiovascular, neurological, inflammatory and immune disease areas. The Company currently has several clinical stage programs involving MultiStem, including for treating inflammatory bowel disease, ischemic stroke, damage caused by myocardial infarction, and for the prevention of graft versus host disease. Athersys has also developed a diverse portfolio that includes other technologies and product development opportunities, and has forged strategic partnerships and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research institutions in the United States and Europe to further develop its platform and products. More information is available at www.athersys.com.
The Athersys, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4548
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These forward-looking statements relate to, among other things, the expected timetable for development of our product candidates, our growth strategy, and our future financial performance, including our operations, economic performance, financial condition, prospects, and other future events. We have attempted to identify forward-looking statements by using such words as "anticipates," "believes," "can," "continue," "could," "estimates," "expects," "intends," "may," "plans," "potential," "should," "suggest," "will," or other similar expressions. These forward-looking statements are only predictions and are largely based on our current expectations. A number of known and unknown risks, uncertainties, and other factors could affect the accuracy of these statements. Some of the more significant known risks that we face that could cause actual results to differ materially from those implied by forward-looking statements are the risks and uncertainties inherent in the process of discovering, developing, and commercializing products that are safe and effective for use as human therapeutics, such as the uncertainty regarding market acceptance of our product candidates and our ability to generate revenues, including MultiStem for the treatment of inflammatory bowel disease, acute myocardial infarction, stroke and other disease indications, and the prevention of graft-versus-host disease. These risks may cause our actual results, levels of activity, performance, or achievements to differ materially from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements. Other important factors to consider in evaluating our forward-looking statements include: our ability to raise additional capital; final results from our MultiStem clinical trials; the possibility of delays in, adverse results of, and excessive costs of the development process; our ability to successfully initiate and complete clinical trials; changes in external market factors; changes in our industry's overall performance; changes in our business strategy; our ability to protect our intellectual property portfolio; our possible inability to realize commercially valuable discoveries in our collaborations with pharmaceutical and other biotechnology companies; our ability to meet milestones under our collaboration agreements; our collaborators' ability to continue to fulfill their obligations under the terms of our collaboration agreements; our possible inability to execute our strategy due to changes in our industry or the economy generally; changes in productivity and reliability of suppliers; and the success of our competitors and the emergence of new competitors. You should not place undue reliance on forward-looking statements contained in this press release, and we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Athersys, Inc.
CONTACT: William (B.J.) Lehmann, J.D.
President and Chief Operating Officer
Tel: (216) 431-9900
bjlehmann@athersys.com
Investor Relations:
Lisa M. Wilson
In-Site Communications
Tel: (917) 543-9932
lwilson@insitecony.com
INVE..$2.28...News...Identive to Acquire Majority Stake in Payment Solution AG
2:05 AM ET 2/1/12 | GlobeNewswire
Identive Group, Inc. (Nasdaq:INVE) (Frankfurt:INV), a provider of products, services and solutions for the identification, security and RFID industries, today announced that it has agreed to acquire a majority stake in payment solution AG, a German-based provider of integrated cashless payment solutions for sports stadiums, arenas, theme parks and other venues for leisure and entertainment throughout Europe.
payment solution's systems enable consumers at sporting and similar events to make quick, cashless payments for food, beverages and merchandise using contactless smart card technology. The systems consist of comprehensive payment management software, smart cards, and reader and communication infrastructure, all supplied and implemented by payment solution. The company offers its customers the option of purchasing of a turnkey solution or entering into a multi-year contract under which payment solution continues to operate and maintain responsibility for the cashless payment system over a set period, in return for sharing in the revenue generated at various events held in the stadium or other venue.
"The acquisition of payment solution enhances our direct connection to consumers and extends our ability to deliver payment systems in Europe," said Ayman S. Ashour, chairman and chief executive officer of Identive Group. "payment solution has proven that they can help stadium operators and merchants increase their revenues through faster transactions in the limited time available for retail at sporting events and concerts. We are also impressed with the company's success in penetrating the Eastern European cashless payment markets and highly value their long-term operations and revenue share agreements."
Hemjö Klein, Chairman of payment solution, stated, "Joining forces with Identive is the right next step for both companies and the market. We have built a strong installed base particularly in the German Soccer Leagues and are convinced the combination with Identive will allow us to expand further into other markets and internationally."
Achim Hirz, CEO of payment solution, commented, "We have worked with Identive as our supplier of cashless payment readers and contactless cards for many years and this partnership has expanded as we have collaborated to develop integrated solutions for various smart city projects. We look forward to deepening our relationship with Identive, which provides us the opportunity to leverage the company's worldwide presence and to further expand our offerings beyond our current base in Germany."
On January 30, 2012, Identive's Swiss-based subsidiary, Bluehill ID AG, entered into agreements with 18 shareholders of payment solution, representing approximately 58.8% of the outstanding share capital of that company. The transaction values 100% of the shares of payment solution at approximately EURO4.0 million (or approximately $5.3 million). Additionally, the company has outstanding debt of approximately EURO4.5 million (or approximately $5.9 million). Under the terms of the agreements, Identive will issue 1,357,758 shares of its common stock to the selling shareholders, representing approximately 2.4% of Identive's outstanding common stock, in exchange for the payment solution shares. The Identive common stock has not been and will not be registered under the U.S. Securities Act of 1933, as amended, and will be issued in reliance upon the safe harbor exemption provided by Regulation S and, therefore, subject to restrictions upon transfer.
About Identive Group
Identive Group, Inc. (Nasdaq:INVE) (Frankfurt:INV) is focused on building the world's signature company in Secure ID. The company's products, software, systems and services address the markets for identity management, physical and logical access control, NFC and a host of RFID-enabled applications for customers in the government, enterprise, consumer, education, healthcare and transportation sectors. Identive's mission is to build a lasting business of scale and technology based on a combination of strong technology-driven organic growth and disciplined acquisitive expansion. For additional info visit: www.identive-group.com.
The Identive Group, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8072
About payment solution
payment solution provides complete and truly integrated payment solutions for stadiums, arenas, theme parks and other venues for leisure and entertainment. Using multi-functional customer cards based on RFID contact-less chip technology and comprehensive management software, the system ensures the seamless interaction of all relevant components such as ticketing, access, point-of-sale, parking, etc. Through increased convenience for guests and visitors, faster transactions and enhanced marketing options, operating companies will enjoy higher revenue and profit.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Identive Group, Inc.
View data
CONTACT: Identive Darby Dye +1 949 553 4251 ddye@identive-group.com Lennart Streibel +49 89 95 95 5195 lstreibel@identive-group.com payment solution Frederik Herr + 49 (0) 40 24 42 41 3-14 Frederik.Herr@paymentsolution.biz
Watching after hour earnings for...CELL...OPWV...RLD..COCO...maybe I can steal some on bad earnings....
GNBT..News..Generex Announces $2.00 Million Capital Investment
Jan 31, 2012 17:27:00 (ET)
WORCESTER, Mass. and TORONTO, Jan. 31, 2012 /PRNewswire via COMTEX/ -- Generex Biotechnology Corporation (the "Company" or "Generex") ( www.generex.com ) (GNBT, Trade ) today announced that it entered into a securities purchase agreement with certain institutional investors on January 31, 2012. The investors have agreed to purchase an aggregate of 2,000 shares of the Company's newly designated non-voting Series B 9% Convertible Preferred Stock ("convertible preferred stock") and warrants to purchase up to an aggregate of 100% of the shares of its common stock issuable upon conversion of the convertible preferred stock ("warrants") at the closing. The convertible preferred stock and warrants will be sold in units, with each unit consisting of one share of convertible preferred stock and a warrant to purchase 100% of the shares of the Company's common stock issuable upon conversion of such share of convertible preferred stock. Each unit will be sold at a negotiated price of $1,000, for an aggregate purchase price of $2,000,000. An aggregate of 26,666,666 shares of the Company's common stock will be issuable upon conversion of, or exercise of, the convertible preferred stock and warrants issued at the closing.
The convertible preferred stock has an effective conversion price of $0.15 per share, subject to adjustment under certain circumstances. The convertible preferred stock will accrue a 9% dividend until February 1, 2015 and, beginning on February 1, 2015 and on each one year anniversary thereafter, such dividend rate will increase by an additional 3%. The dividend will be payable quarterly in cash, or at the Company's option, in shares of common stock. In the event that the convertible preferred stock is converted prior to February 1, 2015, the Company will pay the holder of the converted preferred stock an amount equal to $270 per $1,000 of stated value of the convertible preferred stock, less the amount of all prior quarterly dividends paid on such converted preferred stock before the relevant conversion date. Such "make-whole payment" may be made in cash or, at the Company's option, in shares of its common stock.
Subject to certain ownership limitations, the warrants will be exercisable at any time after their date of issuance and on or before the fifth-year anniversary thereafter at an exercise price of $0.15 per share of common stock, subject to adjustment under certain circumstances. The exercise price and number of shares of common stock issuable upon exercise will also be adjusted if the Company sells or grants any shares of common stock or securities convertible into, or rights to acquire, common stock at an effective price per share that is lower than the then exercise price, except in the event of certain exempt issuances.
Generex intends to use the net proceeds (approximately $1,975,000) from the offering for general corporate purposes.
The closing is expected to take place on or about February 1, 2012 subject to the satisfaction of customary closing conditions.
Seahawk Capital Partners, Inc. will be paid a finder's fee by the Company in connection with this offering. The fee will be paid in shares of the Company's common stock.
The Company and the investors entered into the new securities purchase agreement pursuant to the investors' additional investment rights existing under a July 8, 2011 securities purchase agreement.
This announcement shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The shares of convertible preferred stock, warrants, the shares of common stock underlying the convertible preferred stock and the warrants, and the shares of common stock issuable in lieu of the cash payment of dividends on the convertible preferred stock payable and issuable as finders' fees were offered privately pursuant to Regulation D under the Securities Act of 1933. The Company has agreed with the investors to file a registration statement with the Securities and Exchange Commission covering the public resale of the common stock issuable upon conversion of the preferred stock, issuable as dividends on the preferred stock and issued upon and exercise of the warrants. The Company has agreed to file the registration statement within 45 days after closing and to use its best efforts to have the registration statement declared effective within 120 days after closing.
About Generex Biotechnology Corporation
Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T helper stimulation in immunotherapy. One of its platform technologies relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T helper cells and prevents the further growth of cancer cells. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com .
Cautionary Note Regarding Forward-Looking Statements
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "intend," "may," "plan," "will," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. Risks and uncertainties relating to the offering pursuant to the securities purchase agreement include the risks that (1) all of the conditions to closing of the securities purchase agreement may not be satisfied or waived; (2) provisions of the Delaware General Corporation Law may prohibit the Company from making dividend payments with respect to the convertible preferred stock or make-whole payments that may be due to the holders of the convertible preferred stock; (3) the offering will trigger the price protection feature of certain of the Company's outstanding warrants and dilute current stockholders; (4) Generex may not be able to maintain an effective shelf registration statement covering all the shares of common stock underlying the convertible preferred stock and the warrants and the shares of common stock issuable in lieu of the cash payment of dividends on the convertible preferred stock payable through February 1, 2015; and (5) sales of the Company's common stock issued upon conversion of, or exercise of, the convertible preferred stock and warrants received in the offering may cause the market price of the common stock to fall. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials or ultimate regulatory approval cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials or when it will obtain ultimate regulatory approval by a particular regulatory agency. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
SOURCE Generex Biotechnology Corporation
.
MWWC...very nice CC...contracted clients include Ford...Mazda...Chevy...Fiat..GSI..CC is on the MWWC..site..
WRONG..conference code...should be ...579209
ARRY...$2.75...nice close..
MWWC...conference call today..5pm...218-936-4700..code 579208
PLPL.. .60... good close..
GNBT.. .17 X .1729
GNBT... .17 X .1729
The left one is working the right one is making many mistakes...
RFMK... .0086 X .0087
T.Y..
Lovely...can we get a dime....?